Survival of Primary Brain Tumors in Colombi
Published
May 7, 2020
Almetrics
Dimensions
Google Scholar
Juan Carlos Gómez Vega
https://orcid.org/0000-0002-4385-5063
María Isabel Ocampo Navia
https://orcid.org/0000-0003-1148-7523
Esther De Vries
Oscar Feo Lee
https://orcid.org/0000-0002-4385-5063
María Isabel Ocampo Navia
https://orcid.org/0000-0003-1148-7523
Esther De Vries
Oscar Feo Lee
##plugins.themes.bootstrap3.article.details##
Abstract
Introduction: In 2018, central nervous system tumors represented approximately 1.4% of new cancer diagnoses, causing 2.6% of deaths by cancer. In Colombia, there are few reports on the epidemiology of brain tumors, and those that exist are from local databases that don´t have a rigorous and massive registry. Aim: To determine the survival rates of brain tumors in Colombia. Methods: A retrospective descriptive observational study was conducted, using databases of population-based cancer registries in Colombia. We extracted information from 2003-2012 of patients with tumors without age group restriction. The survival rates were calculated, using the Kaplan-Meier method and the statistical software Stata 14.0. Results: From 2003-2012, 775 adult patients and 123 pediatric patients were reported with a new central nervous system tumor diagnosis in the four cities. The most frequent tumors in the pediatric age group were neuroepithelial tumors, embryonal tumors and ependymal tumors; whereas for adults, the most frequent were neuroepithelial tumors, meningiomas and hematolymphoid tumors. The global survival rate at 6 months, 1 year, 2 years and 3 years, were approximately 49.9%, 35.2%, 21.4% and 15.3% in the pediatric population, and 70.2%, 58.9%, 43.3% and 35.4% in the adult population. Conclusions: The present work constitutes the most recent and multicentric study on the epidemiology of brain tumors in Colombia. There was a clear underreport of this type of tumor and inferior rates compared to universal literature. Despite this, these results will help to widen data recollection and coverage in population-based cancer registries.
Keywords
References
1. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18:v1–75.
2. McNeill KA. Epidemiology of Brain Tumors. Neurol Clin. 2016;34(4):981–98.
3. Coebergh JW, Van Den Hurk C, Louwman M, Comber H, Rosso S, Zanetti R, et al. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. Eur J Cancer. 2015;51(9):1050–63.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
5. Bray F, Piñeros M. Cancer patterns, trends and projections in latin america and the caribbean: A global context. Salud Publica Mex. 2016;58(2):104–17.
6. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol. 2016;135:253–74.
7. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006 Nov;98(21):1528–37.
8. Piñeros M, Sierra MS, Izarzugaza MI, Forman D. Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol. 2016;44:S141–9.
9. Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of Brain Tumors. Neurol Clin. 2018 Aug;36(3):395–419.
10. Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018 Apr;21(2):111–8.
11. Shah V, Kochar P. Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. Recent Pat Anticancer Drug Discov. 2018;13(1):70–85.
12. Fallahi P, Foddis R, Cristaudo A, Antonelli A. High risk of brain tumors in farmers: a mini-review of the literature, and report of the results of a case control study. Clin Ter. 2017;168(5):e290–2.
13. Strowd RE 3rd, Blakeley JO. Common Histologically Benign Tumors of the Brain. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro–oncology):1680–708.
14. Pardo, C. Cendales R. Incidencia, mortalidad y prevalencia de Cáncer en Colombia 2007-2011. Vol. 1, Instituto Nacional De Cancerologia. 2015. 148 p.
15. Kissne Horvath I. Patient registries from the view of health policy. Orv Hetil. 2014 May;155(19):729–31.
16. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2011 Jan;15(3):127–34.
17. Baldi, I., Engelhardt, J., Bonnet, C., Bauchet, L., Berteaud, E., Grüber, A. and Loiseau H. Epidemiology of meningiomas. Neurochirurgie. 2014;Epub:pii: S0028-3770(14)00112-X.
18. Yepez MC, Uribe C, Arias N, Navarro E, de Vries E, Gamboa O, Gil OF PC. Sistema de información de cáncer en Colombia - SICC. Instituto Nacional De Cancerologia. 2017.
19. Instituto Nacional de Cancerología Departamento ministrativo de Estadística Nacional. Sistema de información de cáncer en Colombia-SICC. INC, DANE. 2017.
20. Facultad de Salud-Universidad del Valle. Registro Poblacional de Cáncer de Cali. 2005.
21. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018 Oct;20(suppl_4):iv1-iv86.
22. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017 Nov;19(suppl_5):v1–88.
23. Robles P De, Fiest KM, Frolkis AD, Pringsheim T, Atta C, Germaine- CS, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(October 2014):776–83.
24. Cordera S, Bottacchi E, D’Alessandro G, Machado D, De Gonda F, Corso G. Epidemiology of primary intracranial tumours in NW Italy, a population based study: stable incidence in the last two decades. J Neurol. 2002 Mar;249(3):281–4.
25. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol. 2001 Aug;6(4):183–91.
26. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, et al. Descriptive epidemiology of CNS tumors in France : results from the Gironde Registry for the period 2000 – 2007. 2011;13(12):1370–8.
27. Australian Institute of Health and Welfare. Cancer In australia 2017. 2017.
28. Páez-rodríguez AM, Burbano-erazo NM, Merchancano-delgado CL, Erazo-bravo NJ, Muñoz-bolaños AB. Caracterización de los tumores cerebrales en un Hospital Universitario de Pereira , Colombia : un estudio retrospectivo. Vol. 19. 2013. p. 120–5.
29. Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales A, Madrid L, et al. Long-Term Outcome of 4 , 040 Children Diagnosed With Pediatric Low-Grade Gliomas : An Analysis of the Surveillance Epidemiology and End Results ( SEER ) Database. 2014;(January):1173–9.
30. Burkhard C, Di Patre P-L, Schuler D, Schuler G, Yasargil MG, Yonekawa Y, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003 Jun;98(6):1170–4.
31. Gupta, Nalin; Banerjee, Anuradha; Haas-Kogan D. Pediatric CNS tumors.
32. Hayostek CJ, Shaw EG, Scheithauer B, O’Fallon JR, Weiland TL, Schomberg PJ, et al. Astrocytomas of the cerebellum. A comparative clinicopathologic study of pilocytic and diffuse astrocytomas. Cancer. 1993 Aug;72(3):856–69.
33. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective. J Neurooncol. 2005 Dec;75(3):253–66.
34. Fangusaro J, Hipp SJ, Military SA. Pediatric high grade glioma : a review and update on tumor clinical characteristics and biology. 2012;2(August):1–10.
35. Tulla M, Berthold F, Graf N, Rutkowski S, Schweinitz D Von, Spix C, et al. Incidence , Trends , and Survival of Children With Embryonal Tumors. 2019;136(3).
36. Indelicato DJ, Merchant T, Laperriere N, Lassen Y, Vennarini S, Wolden S, et al. Consensus Report From the Stockholm Pediatric Proton Therapy Conference. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2):387–92.
37. Ostrom QT, Ph D, Gittleman H, Truitt G, Boscia A, Kruchko C, et al. Neuro-Oncology CBTRUS Statistical Report : Primary Brain and Other Central Nervous System Tumors Diagnosed in the. 2018;20:1–86.
38. Association ABT. Glioblastoma and Malignant Astrocytoma.
39. Lim YS, Kim MK, Park BJ, Kim TS, Lim YJ. Long Term Clinical Outcomes of Malignant Meningiomas. 2013;(December 2012):85–90.
40. Anvari K, Kalantari MR, Samini F, Shahidsales S. Assessment of clinicopathologic features in patients with pituitary adenomas in Northeast of Iran : A 13-year retrospective study. 2015;14(4):185–9.
41. Witthayanuwat S, Pesee M, Supaadirek C, Thamronganantasakul K, Krusun S. Survival Analysis of Glioblastoma Multiforme. 2018;19(2009):2613–7.
42. Lieberman F. Glioblastoma update : molecular biology , diagnosis , treatment , response assessment , and translational clinical trials [ version 1 ; referees : 2 approved ] Referee Status : 2017;6(0):1–8.
43. Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S. Survival and prognostic factors for glioblastoma multiforme: Retrospective single-institutional study. Indian J Cancer. 2017;54(1):362–7.
44. Tao S, Cheo T, Lim GH, Hsiu K, Lim C. Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions. 2017;58(1):41–5.
45. Lin N, Yan W, Gao K, Wang Y, Zhang J, You Y. Prevalence and Clinicopathologic Characteristics of the Molecular Subtypes in Malignant Glioma : A Multi- Institutional Analysis of 941 Cases. 2014;9(4):1–5.
46. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol [Internet]. 2011;15(3):127–34. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0123901511700610
47. Merlano CA, Gorbanev I. Health system in Colombia: a systematic review of literature. Gerenc y Políticas Salud. 2013;12(571):74–86.
48. Calderón CAA, Botero JC, Bolaños JO, Martínez RR. Sistema de salud en Colombia: 20 años de logros y problemas. Cien Saude Colet [Internet]. 2011;16(6):2817–28. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232011000600020&lng=en&nrm=iso&tlng=es
49. Planas M, Rodriguez T, Lecha M. La importancia de los datos. Nutr Hosp. 2004;19(1):11–3.
50. Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol. 2008;13(2):102–11.
2. McNeill KA. Epidemiology of Brain Tumors. Neurol Clin. 2016;34(4):981–98.
3. Coebergh JW, Van Den Hurk C, Louwman M, Comber H, Rosso S, Zanetti R, et al. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. Eur J Cancer. 2015;51(9):1050–63.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
5. Bray F, Piñeros M. Cancer patterns, trends and projections in latin america and the caribbean: A global context. Salud Publica Mex. 2016;58(2):104–17.
6. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol. 2016;135:253–74.
7. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006 Nov;98(21):1528–37.
8. Piñeros M, Sierra MS, Izarzugaza MI, Forman D. Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol. 2016;44:S141–9.
9. Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of Brain Tumors. Neurol Clin. 2018 Aug;36(3):395–419.
10. Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018 Apr;21(2):111–8.
11. Shah V, Kochar P. Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. Recent Pat Anticancer Drug Discov. 2018;13(1):70–85.
12. Fallahi P, Foddis R, Cristaudo A, Antonelli A. High risk of brain tumors in farmers: a mini-review of the literature, and report of the results of a case control study. Clin Ter. 2017;168(5):e290–2.
13. Strowd RE 3rd, Blakeley JO. Common Histologically Benign Tumors of the Brain. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro–oncology):1680–708.
14. Pardo, C. Cendales R. Incidencia, mortalidad y prevalencia de Cáncer en Colombia 2007-2011. Vol. 1, Instituto Nacional De Cancerologia. 2015. 148 p.
15. Kissne Horvath I. Patient registries from the view of health policy. Orv Hetil. 2014 May;155(19):729–31.
16. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2011 Jan;15(3):127–34.
17. Baldi, I., Engelhardt, J., Bonnet, C., Bauchet, L., Berteaud, E., Grüber, A. and Loiseau H. Epidemiology of meningiomas. Neurochirurgie. 2014;Epub:pii: S0028-3770(14)00112-X.
18. Yepez MC, Uribe C, Arias N, Navarro E, de Vries E, Gamboa O, Gil OF PC. Sistema de información de cáncer en Colombia - SICC. Instituto Nacional De Cancerologia. 2017.
19. Instituto Nacional de Cancerología Departamento ministrativo de Estadística Nacional. Sistema de información de cáncer en Colombia-SICC. INC, DANE. 2017.
20. Facultad de Salud-Universidad del Valle. Registro Poblacional de Cáncer de Cali. 2005.
21. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018 Oct;20(suppl_4):iv1-iv86.
22. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017 Nov;19(suppl_5):v1–88.
23. Robles P De, Fiest KM, Frolkis AD, Pringsheim T, Atta C, Germaine- CS, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(October 2014):776–83.
24. Cordera S, Bottacchi E, D’Alessandro G, Machado D, De Gonda F, Corso G. Epidemiology of primary intracranial tumours in NW Italy, a population based study: stable incidence in the last two decades. J Neurol. 2002 Mar;249(3):281–4.
25. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol. 2001 Aug;6(4):183–91.
26. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, et al. Descriptive epidemiology of CNS tumors in France : results from the Gironde Registry for the period 2000 – 2007. 2011;13(12):1370–8.
27. Australian Institute of Health and Welfare. Cancer In australia 2017. 2017.
28. Páez-rodríguez AM, Burbano-erazo NM, Merchancano-delgado CL, Erazo-bravo NJ, Muñoz-bolaños AB. Caracterización de los tumores cerebrales en un Hospital Universitario de Pereira , Colombia : un estudio retrospectivo. Vol. 19. 2013. p. 120–5.
29. Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales A, Madrid L, et al. Long-Term Outcome of 4 , 040 Children Diagnosed With Pediatric Low-Grade Gliomas : An Analysis of the Surveillance Epidemiology and End Results ( SEER ) Database. 2014;(January):1173–9.
30. Burkhard C, Di Patre P-L, Schuler D, Schuler G, Yasargil MG, Yonekawa Y, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003 Jun;98(6):1170–4.
31. Gupta, Nalin; Banerjee, Anuradha; Haas-Kogan D. Pediatric CNS tumors.
32. Hayostek CJ, Shaw EG, Scheithauer B, O’Fallon JR, Weiland TL, Schomberg PJ, et al. Astrocytomas of the cerebellum. A comparative clinicopathologic study of pilocytic and diffuse astrocytomas. Cancer. 1993 Aug;72(3):856–69.
33. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective. J Neurooncol. 2005 Dec;75(3):253–66.
34. Fangusaro J, Hipp SJ, Military SA. Pediatric high grade glioma : a review and update on tumor clinical characteristics and biology. 2012;2(August):1–10.
35. Tulla M, Berthold F, Graf N, Rutkowski S, Schweinitz D Von, Spix C, et al. Incidence , Trends , and Survival of Children With Embryonal Tumors. 2019;136(3).
36. Indelicato DJ, Merchant T, Laperriere N, Lassen Y, Vennarini S, Wolden S, et al. Consensus Report From the Stockholm Pediatric Proton Therapy Conference. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2):387–92.
37. Ostrom QT, Ph D, Gittleman H, Truitt G, Boscia A, Kruchko C, et al. Neuro-Oncology CBTRUS Statistical Report : Primary Brain and Other Central Nervous System Tumors Diagnosed in the. 2018;20:1–86.
38. Association ABT. Glioblastoma and Malignant Astrocytoma.
39. Lim YS, Kim MK, Park BJ, Kim TS, Lim YJ. Long Term Clinical Outcomes of Malignant Meningiomas. 2013;(December 2012):85–90.
40. Anvari K, Kalantari MR, Samini F, Shahidsales S. Assessment of clinicopathologic features in patients with pituitary adenomas in Northeast of Iran : A 13-year retrospective study. 2015;14(4):185–9.
41. Witthayanuwat S, Pesee M, Supaadirek C, Thamronganantasakul K, Krusun S. Survival Analysis of Glioblastoma Multiforme. 2018;19(2009):2613–7.
42. Lieberman F. Glioblastoma update : molecular biology , diagnosis , treatment , response assessment , and translational clinical trials [ version 1 ; referees : 2 approved ] Referee Status : 2017;6(0):1–8.
43. Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S. Survival and prognostic factors for glioblastoma multiforme: Retrospective single-institutional study. Indian J Cancer. 2017;54(1):362–7.
44. Tao S, Cheo T, Lim GH, Hsiu K, Lim C. Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions. 2017;58(1):41–5.
45. Lin N, Yan W, Gao K, Wang Y, Zhang J, You Y. Prevalence and Clinicopathologic Characteristics of the Molecular Subtypes in Malignant Glioma : A Multi- Institutional Analysis of 941 Cases. 2014;9(4):1–5.
46. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol [Internet]. 2011;15(3):127–34. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0123901511700610
47. Merlano CA, Gorbanev I. Health system in Colombia: a systematic review of literature. Gerenc y Políticas Salud. 2013;12(571):74–86.
48. Calderón CAA, Botero JC, Bolaños JO, Martínez RR. Sistema de salud en Colombia: 20 años de logros y problemas. Cien Saude Colet [Internet]. 2011;16(6):2817–28. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232011000600020&lng=en&nrm=iso&tlng=es
49. Planas M, Rodriguez T, Lecha M. La importancia de los datos. Nutr Hosp. 2004;19(1):11–3.
50. Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol. 2008;13(2):102–11.
How to Cite
Gómez Vega, J. C., Ocampo Navia, M. I., De Vries, E., & Feo Lee, O. (2020). Survival of Primary Brain Tumors in Colombi. Universitas Medica, 61(3). https://doi.org/10.11144/Javeriana.umed61-3.sobr
Issue
Section
Original Articles